The Quantellect read.As of Nov 19, 2026, 12 active firms cover Evolent Health Inc: 9 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $3.00 to $10.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.09 sits 55% above the current $3.94. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.07 next quarter toward $0.42 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy975%
Neutral325%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.09
+54.8% upside
Average target across 11 active firms as of Nov 19, 2026 vs $3.94 current
Highest Target$10.00
Average Target$6.09
Lowest Target$3.00
Detailed analyst forecasts for EVH
Showing 1–12 of 12 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 9 of 12 active firms rate EVH a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EVH EPS & revenue forecast
EPS · NEXT QUARTER
$0.07
Range $0.01 – $0.13 · 6 analysts · -442% YoY
Next period, 6 analysts expect Evolent Health Inc to earn $0.07 a share (range $0.01 – $0.13), versus $-0.02 a year earlier. Full-year consensus is $0.23, growing to $0.42 the year after.
REVENUE · NEXT QUARTER
$796.7M
Range $688.2M – $893.0M · 6 analysts · +61% YoY
Revenue is expected to reach $796.7M (range $688.2M – $893.0M), +60.5% year-over-year. Full-year consensus is $2.6B, rising to $3.3B next year.
Top analysts covering Evolent Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EVH.
#1
Kevin Caliendo
UBS · Rank #165
Buy
$5.00+27.1% to target
Overall win rate
42%
+ Follow
#2
Richard Close
Canaccord Genuity · Rank #249
Buy
$6.00+52.5% to target
Overall win rate
37%
+ Follow
#3
Constantine Davides
JMP Securities · Rank #454
Buy
$10.00+154.1% to target
Overall win rate
32%
+ Follow
#4
Ryan MacDonald
Needham · Rank #579
Buy
$15.00+281.2% to target
Overall win rate
19%
+ Follow
#5
Jailendra Singh
Truist Securities
Neutral
$6.00+52.5% to target
Coverage
—
+ Follow
EVH stock forecast FAQ
What is EVH's average 12-month price target?+
The 11 active firms with a live target average $6.09 for Evolent Health Inc over the next 12 months, ranging from a $10.00 high to a $3.00 low, as of Nov 19, 2026.
Is EVH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for EVH?+
The Street-high target is $10.00 (Citizens), and the Street-low is $3.00 (RBC Capital). The average of all 11 active-firm targets is $6.09.
How many active Wall Street firms cover EVH?+
12 active firms have a recognized rating on Evolent Health Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EVH?+
Among analysts who currently cover EVH, Kevin Caliendo of UBS has the strongest overall Quantellect track record (Rank #165). Their current call is Buy with a $5.00 target.
What is Evolent Health Inc's projected EPS for next quarter?+
The consensus estimate is $0.07 per share (range $0.01 – $0.13) across 6 analysts. Full-year EPS is projected at $0.23, rising to $0.42 the following year.
How much revenue is Evolent Health Inc expected to report next quarter?+
Consensus revenue is $796.7M (range $688.2M – $893.0M). Full-year revenue is projected at $2.6B, growing to $3.3B next year.
Have analysts been upgrading or downgrading EVH lately?+
As of Nov 19, 2026, 9 of 12 active firms rate EVH a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EVH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.